Segments (Tables)

12 Months Ended

Dec. 31, 2016

Year Ended December 31, 2016	Diagnostics		Therapeutics			Corporate			Total
Lymphoseek sales revenue:
United States (a)	$	16,982,234	$	—		$	—		$	16,982,234
International		54,864		—			—			54,864
Lymphoseek license revenue		1,795,625		—			—			1,795,625
Grant and other revenue		3,012,217		124,766			—			3,136,983
Total revenue		21,844,940		124,766			—			21,969,706
Cost of goods sold, excluding depreciation and amortization		2,192,902		—			—			2,192,902
Research and development expenses, excluding depreciation and amortization		8,120,425		762,151			—			8,882,576
Selling, general and administrative expenses, excluding depreciation and amortization (b)		3,652,154		63,158			8,901,022			12,616,334
Depreciation and amortization (c)		104,138		—			397,231			501,369
Income (loss) from operations (d)		7,775,321		(700,543	)		(9,298,253	)		(2,223,475	)
Other income (expense), excluding equity in the loss of R-NAV, LLC (e)		—		—			(12,070,397	)		(12,070,397	)
Equity in the loss of R-NAV, LLC		—		—			(15,159	)		(15,159	)
Net income (loss)		7,775,321		(700,543	)		(21,383,809	)		(14,309,031	)
Total assets, net of depreciation and amortization:
United States	$	3,610,354	$	15,075		$	8,703,714		$	12,329,143
International		131,752		—			781			132,533
Capital expenditures		—		—			1,847			1,847

Year Ended December 31, 2015	Diagnostics			Therapeutics			Corporate			Total
Lymphoseek sales revenue:
United States (a)	$	10,229,659		$	—		$	—		$	10,229,659
International		24,693			—			—			24,693
Lymphoseek license revenue		1,133,333			—			—			1,133,333
Grant and other revenue		1,861,622			—			—			1,861,622
Total revenue		13,249,307			—			—			13,249,307
Cost of goods sold, excluding depreciation and amortization		1,654,800			—			—			1,654,800
Research and development expenses, excluding depreciation and amortization		12,046,221			730,895			—			12,777,116
Selling, general and administrative expenses, excluding depreciation and amortization (b)		5,852,214			123,884			10,820,392			16,796,490
Depreciation and amortization (c)		281,314			—			290,105			571,419
Loss from operations (d)		(6,585,242	)		(854,779	)		(11,110,497	)		(18,550,518	)
Other income (expense), excluding equity in the loss of R-NAV, LLC (e)		—			—			(9,902,424	)		(9,902,424	)
Equity in the loss of R-NAV, LLC		—			—			(305,253	)		(305,253	)
Benefit from income taxes		—			—			436,051			436,051
Net loss from continuing operations		(6,585,242	)		(854,779	)		(20,882,123	)		(28,322,144	)
Income from discontinued operations, net of tax effect (f)		—			—			758,609			758,609
Net loss		(6,585,242	)		(854,779	)		(20,123,514	)		(27,563,535	)
Total assets, net of depreciation and amortization:
United States	$	3,948,971		$	—		$	10,603,863		$	14,552,834
International		410,666			—			1,013			411,679
Capital expenditures		26,589			—			12,412			39,001

(a)		All sales to Cardinal Health 414 are made in the United States; Cardinal Health 414 distributes the product throughout the U.S. through its network of nuclear pharmacies.
(b)	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.

(c)	Depreciation and amortization is reflected in cost of goods sold ($104,138 and $99,963 for the years ended December 31, 2016 and 2015, respectively), research and development ($0 and $10,617 for the years ended December 31, 2016 and 2015, respectively), and selling, general and administrative expenses ($397,231 and $460,839 for the years ended December 31, 2016 and 2015, respectively).
(d)		Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
(e)		Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
(f)		Amount of contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).